GlucoModicum today announced positive outcomes from a clinical performance study of its needle-free continuous glucose monitor (CGM). Helsinki, Finland-based GlucoModicum said in a news release that the study helps put the company on “a clear path to commercialization.” The study involved 646 participant visits, including individuals with type 2 diabetes and healthy volunteers. The company […]
Clinical Trials
Glucotrack first-in-human study of long-term CBGM implant meets endpoints
Glucotrack (Nasdaq:GCTK) today announced the results from the first-in-human clinical study of its long-term continuous blood glucose monitor (CBGM). Rutherford, New Jersey-based Glucotrack shared findings at the American Diabetes Association’s 85th Scientific Sessions in Chicago. (See all the biggest stories out of ADA 2025 here.) Glucotrack’s device features no on-body external component. The company designed […]
The biggest diabetes tech stories out of ADA 2025
The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]
Mannkind looks to give those with diabetes another option through inhaled insulin
For those living with diabetes, MannKind offers a very different alternative to the current methods of insulin delivery. Founded in 1991 by Alfred E. Mann, a medtech visionary who played a large part in the wider adoption of insulin pumps as the founder of MiniMed, the company develops Afrezza — a fast-acting insulin formulation delivered […]
Modular Medical study shows potential benefits of pump-delivered GLP-1s
Modular Medical (Nasdaq:MODD) has shared new data highlighting the use of its insulin pump technology to deliver GLP-1 therapeutics. The company shared its findings in a poster presentation at the American Diabetes Association’s 85th Scientific Sessions in Chicago. San Diego-based Modular Medical develops the MODD1 product, a 90-day patch pump. It features new microfluidics technology […]
Omnipod 5 rollout for type 2 advances as Insulet pursues next-gen automation
When it comes to the diabetes tech market, the Insulet (Nasdaq:PODD) Omnipod 5 automated insulin delivery system is nothing new. Omnipod 5 first received FDA clearance for individuals aged 6 years old and up with type 1 diabetes in January 2022. At that point, it became the world’s first available tubeless, wearable, automated insulin delivery […]
LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
LifePlus today announced the clinical validation of its LifeLeaf non-invasive and cuffless wearable for continuous glucose and blood pressure tracking. The device delivers real-time insights without needles, invasive sensors or cuffs. Global, multi-center trials conducted across the Mayo Clinic, AMCR Clinic – San Diego Cleveland Clinic – Abu Dhabi, and Hospital Sebarang Jaya – Penang, […]
Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy
A new study has demonstrated proof of concept for a Biolinq continuous sensor in preventing muscle loss during GLP-1 therapy. Investigators presented findings as a late-breaking poster at the American Diabetes Association’s 85th Scientific Sessions in Chicago. Using a DNA-based bioreceptor (aptamer), Biolinq designed its sensor to detect phenylalanine, an essential amino acid. Released from […]
Vaxess study highlights GLP-1 delivery with microarray patch
Vaxess Technologies today shared new preclinical data highlighting the capability of its drug delivery patch to deliver semaglutide. Semaglutide, a GLP-1 receptor agonist, is currently a treatment option for both diabetes and obesity management. Woburn, Massachusetts-based develops a microarray patch (MAP) designed to deliver drugs. It features a soluble microarray with tips that gradually dissolve […]
Lilly to submit once-weekly insulin for regulatory review this year following strong clinical results
Eli Lilly (NYSE:LLY) today announced positive safety and efficacy data for its investigational once-weekly insulin efsitora alfa (efsitora). The QWINT-1, QWINT-3 and QWINT-4 Phase 3 clinical trials evaluated efsitora in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, […]
